Dr. Reddy's Laboratories share news, announcements and annual reports
NSE: DRREDDYBSE: 500124Pharmaceuticals & BiotechnologyMid Cap
Dr. Reddy's Laboratories Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1986 on BSE, May 2003 on NSE
Last close ₹1,342.00down ₹10.00 (0.74%)BSE ₹1,340.25
Share price at the NSE close on 2 Nov 2026. Previous close ₹1,352.00.
2 Nov: open ₹1,352.00, high ₹1,364.90, low ₹1,336.70
52-week range of traded prices to 2 Nov 2026
₹1,101.00Low, 23 Jul 2026₹1,414.90High, 29 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,12,014 Cr104th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 40.01
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.89
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.60%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 7.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 6.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.15
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 20,54,11666.5% delivered
Dr. Reddy's Laboratories share news and announcements
1,702 announcements, routine notices left out, newest first. Page 18 of 35.
Jun 2019
May 2019
Apr 2019
25 Apr · Legal
Exchange has sought clarification from the Company with respect to news item captioned- " Dr Reddy's gets Chinese regulator nod for anti-blood clotting drug ". In this regard, you are advised to provide clarification/confirmation on the news item in detail including the following: a) Whether such event stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order. b) The material impact of this article on the Company. c) Whether company are aware of any information that has not been announced to the Exchanges under Regulation 30 of Listing Regulations. If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under Regulation 30 of the Listing Regulations. The response from the Company is awaited.
Mar 2019
29 Mar · Code of Conduct under SEBI(PIT) Reg., 2015
Feb 2019
Jan 2019